Nanexa’s Senior Scientist Anders Johansson outlines in BioXconomy how the next era of GLP‑1 therapies will be defined not by new molecules, but by smarter delivery. While GLP‑1s have already evolved from twice‑daily injections to once‑weekly dosing, the field is now pushing toward monthly — and even quarterly — regimens to reduce patient burden and improve long‑term adherence. Johansson explains that many ultra‑long‑acting candidates rely on new chemical entities with extended half‑lives, but these approaches come with significant safety, manufacturing and tolerability challenges.

The article highlights an alternative path: using advanced depot technologies to transform existing GLP‑1 drugs into long‑acting formulations. Nanexa’s PharmaShell platform encapsulates GLP‑1 analogues in a nanometer‑thin inorganic coating that prevents burst release and enables controlled dissolution for up to three months. By focusing on delivery rather than redesigning the drug itself, Johansson argues that developers can achieve extended dosing intervals more efficiently — potentially reshaping obesity and diabetes care with fewer injections and better patient experience.

Read the full article here.